(Mis)treating the pharmacogenetic incidentalome
- PMID: 22293554
- DOI: 10.1038/nrd3659
(Mis)treating the pharmacogenetic incidentalome
Abstract
Genome-wide screening is anticipated to accelerate the development of personalized medicine by identifying and exploiting new associations between genomic variants and drug responses. However, this goal could be undermined if care is not taken to minimize the impact of pharmacogenomic associations that turn out to have narrower implications than suggested by initial studies.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources